Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ: ABOS · Real-Time Price · USD
1.350
-0.090 (-6.25%)
Sep 10, 2025, 4:00 PM - Market closed
-6.25%
Market Cap81.77M
Revenue (ttm)n/a
Net Income (ttm)-136.67M
Shares Out 60.57M
EPS (ttm)-2.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume134,624
Open1.460
Previous Close1.440
Day's Range1.350 - 1.465
52-Week Range0.855 - 3.360
Beta0.14
AnalystsStrong Buy
Price Target8.00 (+492.59%)
Earnings DateAug 12, 2025

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sa... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 1, 2021
Employees 61
Stock Exchange NASDAQ
Ticker Symbol ABOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 492.59% from the latest price.

Price Target
$8.0
(492.59% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Daniel O'Connell - CEO & Director Matt Zuga - CFO & Chief Busi...

8 days ago - Seeking Alpha

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

15 days ago - GlobeNewsWire

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants Alex Braun - VP & Head of Investor Relations Daniel J. O'Connell - CEO & Di...

4 weeks ago - Seeking Alpha

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...

4 weeks ago - GlobeNewsWire

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that...

5 weeks ago - GlobeNewsWire

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...

2 months ago - Business Wire

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid bet...

2 months ago - GlobeNewsWire

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer ...

4 months ago - Seeking Alpha

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloi...

4 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...

4 months ago - GlobeNewsWire

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from...

5 months ago - GlobeNewsWire

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Office...

5 months ago - Seeking Alpha

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic tha...

6 months ago - GlobeNewsWire

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DN...

6 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presenta...

6 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amylo...

10 months ago - GlobeNewsWire

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2024 Results Conference Call November 12, 2024 8:00 AM ET Company Participants Alex Braun - Head of Investor Relations Dan O'Connell - Chief Executive Of...

10 months ago - Seeking Alpha

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amylo...

10 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amylo...

11 months ago - GlobeNewsWire

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

NEWTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid bet...

11 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

- Presentation to focus on use of validated pTau217 assay in participant screening process for Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease

11 months ago - GlobeNewsWire

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

WALTHAM, Mass.--(BUSINESS WIRE)--Lucy Therapeutics, Inc. (LucyTx), a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinso...

Other symbols: LENZ
11 months ago - Business Wire

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyl...

1 year ago - GlobeNewsWire

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic tha...

1 year ago - GlobeNewsWire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyl...

1 year ago - GlobeNewsWire